Link to this page
Physician Data Query
| Preferred Name | lipegfilgrastim | |
| Synonyms |
XM22 |
|
| Definitions |
A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101778" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101778" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000732856 |
|
| altLabel |
XM22
|
|
| cui |
C3640212 C4083253
|
|
| DATE FIRST PUBLISHED |
2012-04-30
|
|
| Date last modified |
2012-05-31
|
|
| definition |
A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C101778" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C101778" NCI Thesaurus)
|
|
| NCI ID |
C101778
|
|
| notation |
CDR0000732856
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
lipegfilgrastim
|
|
| tui |
T116 T129 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |